BPMC Share Price Performance
US$129.46
36.49 (39.25%)
0.9% undervalued intrinsic discount
US$130.60
Fair Value
Price US$129.46
AnalystConsensusTarget US$130.60
Fair ValueUS$130.60
Share PriceUS$129.46
0.9% undervalued intrinsic discount
BPMC Community Narratives
AN
Fair Value US$130.60 0.9% undervalued intrinsic discount
Expanding Patient Reach And Pipeline Development Will Unlock Potential
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
BPMC Community Fair Values
- US$130.60FV0.9% undervalued intrinsic discount30.03%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative9users have followed this narrative20 days ago author updated this narrative
Recent BPMC News & Updates
No updates
Blueprint Medicines Corporation Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.41
- Gross Margin
- 96.48%
- Net Profit Margin
- -27.70%
- Debt/Equity Ratio
- 185.4%
Blueprint Medicines Corporation Competitors
About BPMC
- Founded
- 2008
- Employees
- 685
- CEO
- WebsiteView website
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading